Participated · Seed · Mar 2026

Flourish Care, founded in 2020, operates a maternal healthcare platform that matches families with credentialed doulas and delivers a hybrid model of in-person and virtual support. The platform powers referrals, care coordination, and insurance reimbursement and integrates into workflows for health plans, obstetrics, hospitals, FQHCs, and community organizations. Flourish Care reports it has supported thousands of families and is available to more than 20 million covered lives through commercial plans and Medicaid. The company is building an AI-driven risk-prediction engine using clinical and community-reported data to identify patients who may benefit from additional support earlier in pregnancy. Flourish Care positions its model as improving maternal outcomes, reducing unnecessary interventions, and lowering costs as states expand reimbursement for doula care.

Participated · Seed · Jan 2024

Odonata Health is developing a proprietary, textile-based wearable garment embedded with flexible, waterproof sensors to capture maternal and fetal biometric data, including fetal heart rate and rhythm. Signal interpretation relies on proprietary AI algorithms and deep neural networks developed initially in partnership with researchers and clinicians at the Mayo Clinic. The company aims to provide clinicians with early, non-invasive indicators of fetal distress to enable timely intervention and reduce costly hospitalizations. Proceeds from its seed financing are intended to support company formation, product development, clinical validation and regulatory submission efforts. Odonata emphasizes improving access in traditionally under-served communities and is focused on maternal morbidity and mortality reduction. Its products are not yet cleared by the U.S. FDA. Marani Health offers a digital prenatal and postpartum care platform that combines the M•other consumer mobile app with a clinical care web portal to enable two-way communication and data sharing between pregnant mothers and care teams. The M•other app includes educational resources, pregnancy tracking tools, and access to the full Mayo Clinic Guide to a Healthy Pregnancy. The company plans to develop and launch its AI-driven prenatal and postpartum care platform using personalized insights to inform and reduce the cost of care. Marani raised $7.6M in Seed funding to support that development and launch. Backers include OneAlphaNorth Capital and existing investors SWL Healthcare Ventures and TFX Capital. Ann Holder is the founder and CEO, and OneAlphaNorth Managing Director Brady Lipp joined Marani’s board as part of the financing. Marani Health (formerly Odonata Health) develops an AI-powered platform for remote pregnancy care that includes a proprietary sensing device. The company was co-founded with involvement from the Mayo Clinic and aims to improve access to care and outcomes for mothers and babies. Its platform is positioned for use in both telehealth settings and clinics to provide clinicians with more pregnancy-specific data. Marani is advancing toward clinical testing and future market introduction. The company has seen heightened demand for telehealth during the COVID-19 pandemic, which it cites as driving interest in its solution. Leadership changes include the appointment of health care veteran Jodi Hubler to the board.

Participated · Seed · Oct 2023

MDisrupt is an Austin, TX–based marketplace serving the health tech and life sciences industries. Its AI-powered Health Expert Marketplace connects companies with over 2,500 professionals, including clinicians, health system executives, and payor leaders. The platform streamlines access to essential expertise to enable rapid product development and validation. The company raised $1M in funding led by American Heart Association Ventures, and Lisa Suennen joined the MDisrupt board. MDisrupt says it will use the funds to support expanded adoption of its AI-powered marketplace and to add new features through a strategic collaboration with the Association to meet members' needs. The company is led by CEO and founder Ruby Gadelrab. MDisrupt is a marketplace that connects healthtech and life science companies with health experts to help build, commercialize and scale health products. Led by founder and CEO Ruby Gadelrab and based in Austin, TX, the company reports a network of over 1,500 experts from organizations including Blue Cross Blue Shield, CVS, Willis Towers Watson, the U.S. FDA, Optum, and Cleveland Clinic. MDisrupt serves both startups and enterprise customers across healthtech and life science sectors. The company raised $3M in Seed funding and intends to use the capital to launch its platform and expand its client roster. In conjunction with the round, Cat Middleton of The Venture Collective is joining the MDisrupt board of directors. MDisrupt is transforming into a digital health intelligence company that organizes the world's digital health products by performance through clinically crowdsourced data generation. Founded in 2019 and based in Austin, Texas, it connects digital health companies with health industry experts and has helped more than 55 companies build and scale products. The company's platform combines three elements—people, platform, and data—to digitize solutions for access to experts on demand, clinical early adopters, and real-world performance data. MDisrupt plans to expand the platform to enable innovators to rapidly generate the real-world performance data needed to commercialize and scale their products and to serve as a marketplace and benchmark for the industry. The platform's objective dataset, built on real-world clinical performance from every digital health product on the platform, will feed its digital health intelligence engine. The company says the output will influence key decision-makers and provide standards and benchmarks for the growing digital health sector.

Participated · Series A · Sep 2021

Astarte Medical develops NICUtrition®, an EMR-integrated clinical decision support platform that standardizes feeding, optimizes nutrition, and assesses equitable care in neonatal intensive care units. The company applies software and predictive analytics to address malnutrition, suboptimal growth, and racial disparities in NICU care during the first 1,000 days. Astarte has signed contracts and has implementations underway at its initial NICU sites. The company announced a $7.6 million Series A-1 financing to support growth. Management says the funds will be used to scale sales of NICUtrition and expand customer adoption. Wendy Slatery joined the board to provide commercial and market-entry guidance. Astarte Medical is a precision medicine company based in Yardley, Pa., that uses software and predictive analytics to improve outcomes during the first 1,000 days of life, with an initial focus on preterm infants. Its first two solutions, NICUtrition Analytics and NICUtrition Guidance, support feeding protocols, decision-making and nutrition optimization in the neonatal ICU, and include digital tools and diagnostics to standardize feeding and quantify gut health. Led by CEO and co-founder Tracy Warren, the company plans to grow its team by 300% in 2020, adding in-house sales, marketing and client support to assist early adopters. It also intends to expand its engineering and data science teams to support continued product development. Astarte will use the new financing to accelerate hiring and ramp sales and marketing for its NICUtrition products, develop a regulatory strategy in support of a 2020 MAGI trial, and build a health disparities platform. The company additionally plans to explore and isolate novel therapeutic and diagnostic candidates. Astarte Medical develops NICUtrition®, a suite of digital tools and diagnostics that support feeding protocols, decision-making and practice in the neonatal ICU. The platform is designed to standardize feeding, optimize nutrition and quantify gut health for preterm infants. Core to Astarte’s product is a proprietary dataset that integrates feeding protocols, microbial profiles and clinical information to enable predictive analytics. The company focuses on improving outcomes during the first 1,000 days of life, with an initial emphasis on premature infants. Astarte recently graduated from the Illumina Accelerator and is led by CEO and co-founder Tracy Warren. The company is based in Yardley, Pa., and will use the Series A proceeds to complete development of the NICUtrition suite. Astarte Medical develops software to support care of preterm infants by providing quantitative data about gut health to enable personalized care and nutrition. Its first product, NICUtrition Guidance, is a rules engine designed to standardize enteral feeding for preterm infants. The company plans to develop MAGI, a gut-health score intended to improve growth and development of preemies while lowering medical treatment costs. Astarte was co-founded by Tracy Warren, Tammi Jantzen, and Katherine Gregory and is based in Yardley, PA. The company has received an investment from Next Act Fund and is currently raising money to launch and support NICUtrition Guidance. The amount of the investment disclosed in the article was not provided.